In a 76-year-old man with atrial fibrillation on rivaroxaban (Xarelto) and a history of alcohol use who presents with fatigue, anorexia, weight loss, and persistent macrocytosis despite a normalized hemoglobin, does the new laboratory data change your initial management, and what should be the next diagnostic and therapeutic approach?

Approach to Persistent Macrocytosis with Constitutional Symptoms in an Elderly Patient on Rivaroxaban

Yes, the new laboratory findings significantly change your management—the combination of persistent macrocytosis, constitutional symptoms (fatigue, anorexia, weight loss), immature granulocytes, and urinary bilirubin in a 76-year-old man warrants immediate evaluation for myelodysplastic syndrome (MDS) with bone marrow examination, even though hemoglobin has normalized. 1

Critical Red Flags Requiring Urgent Action

The presence of immature granulocytes (1%) on peripheral smear is a dysplastic feature that raises strong suspicion for MDS, particularly when combined with persistent macrocytosis and constitutional symptoms in an elderly patient. 1 The NCCN emphasizes that MDS should be strongly considered in elderly individuals with isolated macrocytic anemia, constitutional symptoms, and normal B12/folate levels—which your patient has already demonstrated. 1

Do not attribute the macrocytosis solely to alcohol use in this clinical context—the NCCN specifically cautions against this common pitfall, as delaying MDS diagnosis in older patients with unexplained cytopenias and systemic symptoms adversely affects prognosis and limits therapeutic options. 1

Immediate Diagnostic Workup

Essential Laboratory Studies

• Peripheral blood smear review to identify dysplastic erythroid or granulocytic cells, hypersegmented neutrophils (≥6 nuclear lobes in ≥10% of cells), blasts, or other multilineage abnormalities. 1

• Reticulocyte count to distinguish between production versus destruction causes—a low or normal reticulocyte count with macrocytosis suggests vitamin B12 deficiency, folate deficiency, MDS, medications, or hypothyroidism. 2, 1

• Methylmalonic acid (MMA) level if B12 is borderline (180-350 pg/mL)—MMA >271 nmol/L confirms functional B12 deficiency despite "normal" serum levels. 1

• Complete metabolic panel with LDH and indirect bilirubin to evaluate for hemolysis, given the urinary bilirubin finding. 2

• Transferrin saturation and ferritin because a wide red cell distribution width (RDW) can indicate coexisting iron deficiency even with macrocytosis, and in inflammatory states ferritin up to 100 μg/L may still indicate iron deficiency. 2, 1

Bone Marrow Examination Indications

Proceed immediately to bone marrow aspiration and biopsy with cytogenetic studies given the following criteria are met: 1

• Persistent constitutional symptoms without alternative explanation
• Low or normal reticulocyte count with unexplained macrocytosis
• Dysplastic features (immature granulocytes) on peripheral smear
• Elderly patient with weight loss and anorexia

The bone marrow evaluation must include: 1

• Morphologic assessment for dysplasia in erythroid, granulocytic, and megakaryocytic lineages (≥10% dysplasia in any lineage supports MDS diagnosis)
• Blast percentage determination (5-19% blasts in marrow confirms MDS)
• Cytogenetic analysis (critical for both diagnosis and prognostication)
• Flow cytometry to quantify CD34+ cells and exclude paroxysmal nocturnal hemoglobinuria (PNH) clone

Rivaroxaban-Specific Considerations

Bleeding Risk Assessment

Your patient has multiple modifiable bleeding risk factors while on rivaroxaban: 3

• Advanced age (76 years) increases bleeding risk by HR 1.25 per 5-year increment 3
• History of alcohol use (HR 2.37 for heavy use) 3
• Recent epistaxis suggests mucosal bleeding tendency

The presence of even one modifiable bleeding risk factor doubles the risk of major bleeding on rivaroxaban. 3 In elderly patients ≥75 years, rivaroxaban increases gastrointestinal bleeding risk compared to other anticoagulants. 4, 5

Renal Function Monitoring

Monitor renal function urgently given the patient's age and constitutional symptoms—rivaroxaban dosing depends critically on creatinine clearance. 2, 4 The 15 mg dose should ONLY be used in patients with CrCl 30-50 mL/min; using this dose in patients with normal renal function provides subtherapeutic anticoagulation. 6 Conversely, standard 20 mg dosing in patients with declining renal function increases bleeding risk. 7

In elderly patients with renal insufficiency, coagulation monitoring should be considered despite manufacturer recommendations, as PT and aPTT abnormalities may develop and persist even after drug discontinuation. 7

Bone Marrow Suppression Risk

The FDA label for rivaroxaban (though this appears to be mislabeled carbamazepine data in the evidence) emphasizes that if evidence of significant bone marrow depression develops: 8

1. Stop the drug immediately
2. Perform daily CBC, platelet, and reticulocyte counts
3. Obtain bone marrow aspiration and trephine biopsy immediately

Management Algorithm

Step 1: Immediate Actions (Within 24-48 Hours)

• Order peripheral blood smear review by hematopathologist 1
• Check reticulocyte count, MMA, LDH, indirect bilirubin, haptoglobin 2, 1
• Assess renal function (creatinine, calculated CrCl) 2, 4
• Review rivaroxaban dosing appropriateness based on renal function 2, 6

Step 2: Hematology Referral (Within 1 Week)

Refer to hematology immediately for bone marrow evaluation given: 2, 1

• Persistent macrocytosis with immature granulocytes
• Constitutional symptoms (fatigue, anorexia, weight loss)
• Age 76 years
• Normal B12/folate already documented

Step 3: Anticoagulation Management Pending Workup

Continue rivaroxaban at appropriate dose unless bleeding complications develop, but: 2, 3

• Eliminate modifiable bleeding risk factors: counsel on alcohol cessation (HR 2.37 for major bleeding) 3
• Avoid concomitant NSAIDs, aspirin, or other antiplatelets unless compelling cardiovascular indication (HR 1.80 for major bleeding with concomitant use) 3
• Monitor for bleeding symptoms at each encounter 6

If bone marrow biopsy confirms MDS with significant cytopenias, consider switching to apixaban 5 mg twice daily (or 2.5 mg twice daily if age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL), which may have lower gastrointestinal bleeding risk than rivaroxaban in elderly patients. 4, 5

Common Pitfalls to Avoid

1. Do not dismiss macrocytosis as "just alcohol-related" in an elderly patient with constitutional symptoms—this delays MDS diagnosis. 1

2. Do not wait for anemia to worsen before pursuing bone marrow evaluation—the presence of dysplastic features (immature granulocytes) is sufficient indication. 1

3. Do not assume "normal" B12 levels exclude deficiency—check MMA if B12 is 180-350 pg/mL. 1

4. Do not overlook coexisting iron deficiency—check RDW, transferrin saturation, and ferritin, as microcytosis and macrocytosis can mask each other. 2, 1

5. Do not continue rivaroxaban at inappropriate doses for renal function—verify CrCl and adjust accordingly. 2, 6

6. Do not ignore the bleeding risk of continuing rivaroxaban if MDS with thrombocytopenia is diagnosed—early hematology consultation is essential. 1, 8